In a randomized controlled trial, 11,324 patients with pre-existing coronary heart disease (CHD) were randomly allocated to either 300 mg vitamin E, 850 mg omega-3 fatty acid ethyl esters (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), both, or no treatment and followed for 3.5 years. In the end, a 15% reduction in mortality, nonfatal heart attack (myocardial infarction), and nonfatal stroke was seen in participants taking 850 mg omega-3 fatty acid alone. Compared to the no treatment group, participants taking omega-3 fatty acid after 6-months experienced a 2.5% increase in HDL (“good”) cholesterol and a 4% reduction in triglycerides, a type of fat in the bloodstream and fat tissue that can contribute to the hardening and narrowing of arteries. As a group, those taking this dietary supplementation experienced a 20% reduction in all-cause mortality and a 45% reduction in sudden death. The results indicate that in patients who have CHD, omega-3 fatty acid supplements, but not vitamin E, significantly reduce mortality. (7)
Next Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125